We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Novel Capsule Releases Microscopic Robots into Colon to Treat Inflammatory Bowel Disease

By HospiMedica International staff writers
Posted on 28 Jun 2024

Inflammatory bowel disease (IBD) is an autoimmune disorder marked by chronic inflammation of the digestive tract, affecting millions globally with symptoms like severe abdominal pain, rectal bleeding, diarrhea, and weight loss. More...

IBD is triggered when immune cells, specifically macrophages, become overly active and produce high levels of inflammation-inducing proteins known as pro-inflammatory cytokines. These cytokines bind to macrophage receptors, stimulating further cytokine production and perpetuating the inflammation cycle, which results in the debilitating symptoms associated with IBD. Researchers have now developed a novel approach involving a pill that releases microrobots in the colon to combat IBD, which has demonstrated effectiveness in reducing IBD symptoms and promoting the repair of damaged colon tissue in mice, without any toxic side effects.

The microrobots, engineered by scientists at the University of California San Diego (La Jolla, CA, USA), are composed of green algae cells bonded chemically with anti-inflammatory nanoparticles. The nanoparticles capture and neutralize pro-inflammatory cytokines in the gut, while the motile green algae cells distribute the nanoparticles throughout the colon, enhancing cytokine removal and aiding tissue healing. The effectiveness of the nanoparticles lies in their biomimetic design, crafted from biodegradable polymer and coated with macrophage cell membranes to serve as decoys. These decoys attract cytokines without triggering additional cytokine production, thus breaking the inflammatory cycle.

The safety of these biohybrid microrobots has been thoroughly evaluated. Built from biocompatible materials, the green algae used are deemed safe by the U.S. Food and Drug Administration. Encapsulated in a liquid-filled capsule with a pH-responsive coating, the microrobots are protected from stomach acid but released in the colon’s neutral pH, ensuring targeted delivery to the inflammation site. This precision minimizes potential toxicity to other organs. The microrobots remain in liquid form within the capsule until released. When administered orally to mice with IBD, this innovative treatment reduced fecal bleeding, enhanced stool consistency, counteracted weight loss, and reduced colonic inflammation, all without noticeable side effects. The research team is now progressing towards clinical trials of this microrobot treatment.

“The beauty of this approach is that it’s drug-free—we just leverage the natural cell membrane to absorb and neutralize pro-inflammatory cytokines,” said Liangfang Zhang, a professor in the Aiiso Yufeng Li Family Department of Chemical and Nano Engineering at UC San Diego.

Related Links:
UC San Diego


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.